Teva Pharmaceutical Industries Limited..（TEVA）の財務TEVATeva Pharmaceutical Industries Limited..

Teva Pharmaceutical Industries Limited (TEVA) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Generic products, accounting for 50.8% of total sales, equivalent to $2.10B. Other significant revenue streams include AUSTEDO and AJOVY. Understanding this composition is critical for investors evaluating how TEVA navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Teva Pharmaceutical Industries Limited maintains a gross margin of 50.82%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 11.96%, while the net margin is -2.54%. These profitability ratios, combined with a Return on Equity (ROE) of 9.68%, provide a clear picture of how effectively TEVA converts its operational activities into shareholder value.

In the context of the broader market, TEVA competes directly with industry leaders such as BNOX. With a market capitalization of $47.93B, it holds a leading position in the sector. When comparing efficiency, TEVA's gross margin of 50.82% stands against BNOX's N/A. Such benchmarking helps identify whether Teva Pharmaceutical Industries Limited is trading at a premium or discount relative to its financial performance.

Teva's gross margin has improved to 52.29% in Q2 2026, up from 49.28% in Q1 2026, indicating better cost management and profitability. The forward P/E ratio is 12.55, suggesting the stock is relatively undervalued compared to its earnings potential.